• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丙型肝炎治疗护理协调的成本补偿模式。

A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination.

作者信息

Behrends Czarina N, Eggman Ashley A, Gutkind Sarah, Bresnahan Marie P, Fluegge Kyle, Laraque Fabienne, Litwin Alain H, Meissner Paul, Shukla Shuchin J, Perumalswami Ponni V, Weiss Jeffrey, Wyatt Brooke E, Schackman Bruce R

机构信息

Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York (Drs Behrends and Schackman and Mss Eggman and Gutkind); New York City Department of Health & Mental Hygiene, Queens, New York (Ms Bresnahan and Drs Fluegge and Laraque); Albert Einstein College of Medicine, Bronx, New York (Drs Litwin and Shukla and Mr Meissner); Montefiore Medical Center, Bronx, New York (Drs Litwin and Shukla); Icahn School of Medicine at Mount Sinai, New York, New York (Drs Perumalswami and Weiss); and Mount Sinai Hospital, New York, New York (Dr Perumalswami and Ms Wyatt).

出版信息

J Public Health Manag Pract. 2019 May/Jun;25(3):253-261. doi: 10.1097/PHH.0000000000000806.

DOI:10.1097/PHH.0000000000000806
PMID:29975342
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6314903/
Abstract

OBJECTIVE

To estimate the cost of delivering a hepatitis C virus care coordination program at 2 New York City health care provider organizations and describe a potential payment model for these currently nonreimbursed services.

DESIGN

An economic evaluation of a hepatitis C care coordination program was conducted using micro-costing methods compared with macro-costing methods. A potential payment model was calculated for 3 phases: enrollment to treatment initiation, treatment initiation to treatment completion, and a bonus payment for laboratory evidence of successful treatment outcome (sustained viral response).

SETTING

Two New York City health care provider organizations.

PARTICIPANTS

Care coordinators and peer educators delivering care coordination services were interviewed about time spent on service provision. De-identified individual-level data on study participant utilization of services were also used.

INTERVENTION

Project INSPIRE is an innovative hepatitis C care coordination program developed by the New York City Department of Health and Mental Hygiene.

MAIN OUTCOME MEASURES

Average cost per participant per episode of care for 2 provider organizations and a proposed payment model.

RESULTS

The average cost per participant at 1 provider organization was $787 ($522 nonoverhead cost, $264 overhead) per episode of care (5.6 months) and $656 ($429 nonoverhead cost, $227 overhead, 5.7 months) at the other one. The first organization had a lower macro-costing estimate ($561 vs $787) whereas the other one had a higher macro-costing estimate ($775 vs $656). In the 3-phased payment model, phase 1 reimbursement would vary between the provider organizations from approximately $280 to $400, but reimbursement for both organizations would be approximately $220 for phase 2 and approximately $185 for phase 3.

CONCLUSIONS

The cost of this 5.6-month care coordination intervention was less than $800 including overhead or less than $95 per month. A 3-phase payment model is proposed and requires further evaluation for implementation feasibility. Project INSPIRE's HCV care coordination program provides good value for a cost of less than $95 per participant per month. The payment model provides an incentive for successful cure of hepatitis C with a bonus payment; using the bonus payment to support HCV tele-mentoring expands HCV treatment capacity and empowers more primary care providers to treat their own patients with HCV.

摘要

目的

评估在纽约市的2家医疗服务机构实施丙型肝炎病毒护理协调项目的成本,并描述针对这些目前未获报销服务的潜在支付模式。

设计

采用微观成本核算方法与宏观成本核算方法对丙型肝炎护理协调项目进行经济评估。计算了3个阶段的潜在支付模式:登记至开始治疗、开始治疗至治疗结束,以及针对治疗成功结果(持续病毒学应答)的实验室证据的奖金支付。

地点

纽约市的2家医疗服务机构。

参与者

就提供护理协调服务所花费的时间,对提供护理协调服务的护理协调员和同伴教育者进行了访谈。还使用了关于研究参与者服务利用情况的匿名个人层面数据。

干预措施

“激励计划”(INSPIRE)项目是纽约市卫生和精神卫生部门开发的一项创新性丙型肝炎护理协调项目。

主要结局指标

2家医疗服务机构每位参与者每次护理的平均成本以及一种提议的支付模式。

结果

1家医疗服务机构每位参与者每次护理(5.6个月)的平均成本为787美元(非间接费用成本522美元,间接费用264美元),另一家为656美元(非间接费用成本429美元,间接费用227美元,5.7个月)。第一家机构的宏观成本核算估计较低(561美元对787美元),而另一家的宏观成本核算估计较高(775美元对656美元)。在三阶段支付模式中,第一阶段的报销在各医疗服务机构之间从约280美元到400美元不等,但两家机构在第二阶段的报销约为220美元,第三阶段约为185美元。

结论

这项为期5.6个月的护理协调干预措施的成本,包括间接费用在内不到800美元,即每月不到95美元。提出了一种三阶段支付模式,需要对其实施可行性进行进一步评估。“激励计划”项目的丙型肝炎护理协调项目以每位参与者每月不到95美元的成本提供了良好价值。该支付模式通过奖金支付为丙型肝炎的成功治愈提供了激励;利用奖金支付来支持丙型肝炎远程指导扩大了丙型肝炎治疗能力,并使更多初级保健提供者能够治疗自己的丙型肝炎患者。

相似文献

1
A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination.丙型肝炎治疗护理协调的成本补偿模式。
J Public Health Manag Pract. 2019 May/Jun;25(3):253-261. doi: 10.1097/PHH.0000000000000806.
2
Evaluation of a hepatitis C clinical care coordination programme's effect on treatment initiation and cure: A surveillance-based propensity score matching approach.丙型肝炎临床护理协调项目对治疗启动和治愈效果的评估:基于监测的倾向评分匹配方法。
J Viral Hepat. 2018 Nov;25(11):1236-1243. doi: 10.1111/jvh.12929. Epub 2018 May 24.
3
Cost of providing co-located hepatitis C treatment at a syringe service program exceeds potential reimbursement: Results from a clinical trial.在注射器服务项目中提供同址丙型肝炎治疗的成本超过了潜在报销额度:一项临床试验的结果。
Drug Alcohol Depend Rep. 2022 Dec;5. doi: 10.1016/j.dadr.2022.100109. Epub 2022 Oct 7.
4
Development and Validation of Surveillance-Based Algorithms to Estimate Hepatitis C Treatment and Cure in New York City.基于监测的纽约市丙型肝炎治疗和治愈估计算法的开发和验证。
J Public Health Manag Pract. 2018 Nov/Dec;24(6):526-532. doi: 10.1097/PHH.0000000000000688.
5
Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.取消医疗补助按服务付费的丙型肝炎病毒(HCV)治疗限制对纽约市医疗补助管理式医疗组织中HCV医疗服务提供者体验的影响
J Urban Health. 2021 Aug;98(4):563-569. doi: 10.1007/s11524-020-00422-0.
6
Design and impact of bundled payment for detox and follow-up care.捆绑支付在戒毒和随访护理中的设计和影响。
J Subst Abuse Treat. 2017 Nov;82:113-121. doi: 10.1016/j.jsat.2017.09.012. Epub 2017 Sep 21.
7
Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs.丙型肝炎护理促进成本:感染 HIV 和丙型肝炎的吸毒者
Drug Alcohol Depend. 2022 Mar 1;232:109265. doi: 10.1016/j.drugalcdep.2022.109265. Epub 2022 Jan 10.
8
Evaluating reimbursement of integrated support services using chronic care management (CCM) codes for treatment of hepatitis C among Medicare beneficiaries.使用慢性护理管理(CCM)代码评估医疗保险受益人中丙型肝炎治疗综合支持服务的报销情况。
J Healthc Risk Manag. 2019 Oct;39(2):31-40. doi: 10.1002/jhrm.21389. Epub 2019 Aug 30.
9
The effects of medical group practice and physician payment methods on costs of care.医疗集团执业和医生支付方式对医疗成本的影响。
Health Serv Res. 2000 Aug;35(3):591-613.
10
Developing a costing framework for palliative care services.制定姑息治疗服务的成本核算框架。
J Pain Symptom Manage. 2014 Oct;48(4):719-29. doi: 10.1016/j.jpainsymman.2013.11.017. Epub 2014 Apr 5.

引用本文的文献

1
Cost of providing co-located hepatitis C treatment at a syringe service program exceeds potential reimbursement: Results from a clinical trial.在注射器服务项目中提供同址丙型肝炎治疗的成本超过了潜在报销额度:一项临床试验的结果。
Drug Alcohol Depend Rep. 2022 Dec;5. doi: 10.1016/j.dadr.2022.100109. Epub 2022 Oct 7.
2
Closing the hepatitis C treatment gap: United States strategies to improve retention in care.消除丙型肝炎治疗差距:美国改善患者治疗保留率的策略。
J Viral Hepat. 2022 Aug;29(8):588-595. doi: 10.1111/jvh.13685. Epub 2022 May 26.
3
Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs.

本文引用的文献

1
Check Hep C: A Community-Based Approach to Hepatitis C Diagnosis and Linkage to Care in High-Risk Populations.检查丙型肝炎:一种基于社区的丙型肝炎诊断及高危人群护理衔接方法。
J Public Health Manag Pract. 2018 Jan/Feb;24(1):41-48. doi: 10.1097/PHH.0000000000000519.
2
Medicare Payment for Behavioral Health Integration.医疗保险对行为健康整合的支付
N Engl J Med. 2017 Feb 2;376(5):405-407. doi: 10.1056/NEJMp1614134. Epub 2016 Dec 14.
3
Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States.
丙型肝炎护理促进成本:感染 HIV 和丙型肝炎的吸毒者
Drug Alcohol Depend. 2022 Mar 1;232:109265. doi: 10.1016/j.drugalcdep.2022.109265. Epub 2022 Jan 10.
4
A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure.用于诊断但未经治疗的丙型肝炎的数字病例发现算法:提高治疗和治愈机会的工具。
Hepatology. 2021 Dec;74(6):2974-2987. doi: 10.1002/hep.32086.
5
Innovations in Hepatitis C Screening and Treatment.丙型肝炎的筛查和治疗创新。
Hepatol Commun. 2020 Dec 7;5(3):371-386. doi: 10.1002/hep4.1646. eCollection 2021 Mar.
6
Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.取消医疗补助按服务付费的丙型肝炎病毒(HCV)治疗限制对纽约市医疗补助管理式医疗组织中HCV医疗服务提供者体验的影响
J Urban Health. 2021 Aug;98(4):563-569. doi: 10.1007/s11524-020-00422-0.
美国慢性丙型肝炎患者获得口服抗病毒治疗的机会。
J Clin Transl Hepatol. 2016 Jun 28;4(2):76-82. doi: 10.14218/JCTH.2016.00011. Epub 2016 Jun 15.
4
Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study.医疗保险患者获得丙型肝炎新药的情况:一项回顾性队列研究。
J Manag Care Spec Pharm. 2016 Jun;22(6):714-722b. doi: 10.18553/jmcp.2016.22.6.714.
5
Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States.美国丙型肝炎病毒直接抗病毒治疗方案的价格与可及性
Infect Agent Cancer. 2016 May 16;11:24. doi: 10.1186/s13027-016-0071-z. eCollection 2016.
6
Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.按保险类型划分的现代丙型肝炎治疗绝对拒绝率的差异
Clin Gastroenterol Hepatol. 2016 Jul;14(7):1035-43. doi: 10.1016/j.cgh.2016.03.040. Epub 2016 Apr 5.
7
The Impact of Comprehensive Case Management on HIV Client Outcomes.综合病例管理对艾滋病病毒感染者治疗效果的影响。
PLoS One. 2016 Feb 5;11(2):e0148865. doi: 10.1371/journal.pone.0148865. eCollection 2016.
8
Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.州医疗补助计划下新型丙型肝炎病毒治疗的获取受限。
Ann Intern Med. 2015 Aug 4;163(3):226-8. doi: 10.7326/M15-0320.
9
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.美国医疗补助计划对索磷布韦治疗丙型肝炎病毒感染的报销限制。
Ann Intern Med. 2015 Aug 4;163(3):215-23. doi: 10.7326/M15-0406.
10
The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis.美国慢性丙型肝炎病毒感染的治疗流程:一项系统评价与荟萃分析
PLoS One. 2014 Jul 2;9(7):e101554. doi: 10.1371/journal.pone.0101554. eCollection 2014.